After the 14‐day period of decitabine pretreatment, the leukemic cells were subjected to synergy testing, using 5 nM decitabine in combination with prednisone, asparaginase, cytarabine, daunorubicin, or vincristine, which are currently used in the treatment of MLL‐rearranged infant ALL. Here, KMT2A is linked to acute lymphoblastic leukemia.